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Abstract 
Introduction: Human papilloma virus (HPV) is a sexually transmitted infection that is known to 
cause genital warts and cervical, oropharyngeal, anal, vulvar, penile, vaginal, and rectal cancers.  
There are vaccines available to prevent HPV infections.  Primary prevention is our best strategy 
to combat the spread of HPV.   
Project Aim: The purpose of this quality improvement project is to determine if a provider 
recommendation will increase human papilloma virus (HPV) vaccine uptake in adolescents.  
Project Method: Using the Model for Improvement as the conceptual framework, the providers 
at a private pediatric practice were taught to use a presumptive presentation for HPV vaccine and 
co-administration with Tdap and meningococcal vaccine.  This practice change required parents 
to opt out of HPV vaccine rather than opting into HPV vaccine.  Providers also provided 
education on HPV and benefits of HPV vaccine to parents and adolescents. 
Data Collection and Analysis: Prior to initiation of the intervention, retrospective data was 
collected on HPV acceptance rate in the clinic.  One month and two months after the 
introduction of the intervention, data was collected to determine if there was a significant change 
in HPV vaccine uptake.  Data was obtained from the patients’ electronic medical records. 
Results:  This quality improvement change determined that provider recommendation alone was 
not effective in increasing HPV vaccine acceptance with the addition of parental awareness 
measures, HPV compliance rate increased approximately 15%. 
Keywords: human papillomavirus, human papillomavirus vaccine, immunization, immunization 
rates, provider recommendation 
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Introduction 
 Human papillomavirus (HPV) is the most common sexually transmitted infection 
worldwide and is known to cause genital warts and cervical, oropharyngeal, anal, vulvar, penile, 
vaginal, and rectal cancers (Dayal, Robinson, Schoening, Smith, & Kim, 2016; Gerend, 
Shepherd, Lustria, & Shepherd, 2016; Scott & Batty, 2016).  There are 14 million new HPV 
infections every year, with a lifetime disease probability of greater than 80% for women and 
90% for men (Dayal et al., 2016).  HPV vaccine offers protection against at least 70% of cervical 
cancer incidence and 90% of genital warts incidence (Rahman Laz, McGrath, & Berenson, 
2015).  The only HPV vaccine on the market in the United States is Gardasil 9®; this vaccine is 
a 9-valent vaccine that protects against two strains that cause genital warts and nine oncogenic 
HPV genotypes (National Cancer Institute, 2018).   
 Healthy People 2020 has a target of an 80% series completion rate for HPV vaccine 
(Office of Disease Prevention and Health Promotion [ODPHP], 2017).  Statistics from the 
Centers for Disease Control and Prevention (CDC) (2016) reported that six out of ten parents 
nationwide are getting the HPV vaccine for their children; Kansas’ compliance rate is only 50-
59%.  HPV vaccine is approved for males and females ages 9-45 years and it is recommended to 
initiate the series at age 11 or 12 (American Academy of Pediatrics [AAP], 2017; CDC, 2016).  
Two additional vaccines are recommended at these ages, tetanus/diphtheria/pertussis (Tdap) and 
a meningococcal vaccine (AAP, 2017; CDC 2016).  The rate of compliance for Tdap is 87.6%, 
meningococcal vaccine is 79.3%, and HPV vaccine is 60% (Ogunbajo, Hansen, North, Okoloko, 
& Niccolai, 2016). There is a clear difference in vaccine uptake and a need to increase HPV 
vaccine compliance rates.   
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 To understand why HPV vaccine rates are so low and what providers can do to increase 
acceptance of HPV vaccine, a literature review was conducted to determine the factors that 
influence parents to accept or decline the vaccine and methods to increase uptake.  Using this 
knowledge, a quality improvement project has been created and introduced at a private practice 
pediatric office in Prairie Village, Kansas (see Appendix A). 
Literature Review 
 To recognize why parents accept or decline HPV vaccine, this author conducted a 
literature review to discover the barriers to HPV vaccine uptake, factors that increase HPV 
vaccine acceptance, and strategies to promote vaccine acceptance.  Databases utilized were Pub 
Med and CINAHL.  Search terms were “HPV vaccine”, “human papillomavirus vaccine”, and 
“provider recommendation”.  Journal articles were excluded if they were published prior to 2012 
and if primary research was not conducted.   
Barriers to HPV Vaccine Uptake 
 To understand why HPV vaccine has a lower compliance rate compared to other 
vaccines, this author reviewed literature and found the four main barriers toward initiation.  The 
barriers include: (a) concerns about side effects of HPV vaccine; (b) insufficient or no 
knowledge about HPV and HPV vaccine; (c) lack of provider recommendation; and (d) 
adolescent is not sexually active and parental concern that receiving HPV vaccine will initiate 
sexual debut (Argones et al, 2016; Dayal et al., 2016; Gerend et al., 2016, Sanderson et al., 2017, 
Shay et al., 2016; Wilson et al., 2013).   
 Concerns about side effects of HPV vaccine.  Multiple studies revealed that parents 
were concerned about the side effects of HPV vaccines (Dayal et al, 2016; Sanderson et al., 
2017; Wilson et al, 2016).  Sanderson et al. (2017) found that parents had multiple hesitations 
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toward the initiation of HPV vaccine, with concerns for safety and side effects ranked as the 
number one reason (Sanderson et al., 2017).  Wilson et al. (2016) put together a focus group of 
ethnically diverse black woman and discovered similar results.  These participants stated that 
they did not accept HPV vaccine for their children because they were concerned about side 
effects such as autism and had a general distrust of vaccines all together (Wilson et al, 2016).  
Dayal et al. (2016) found if parents perceived HPV vaccine to be harmful, they were less likely 
to vaccinate their child.   
 Lack of recommendation.  Many vaccines are presented using a presumptive 
presentation making the parents opt out of the vaccine versus opting in; HPV vaccine on the 
other hand is often offered as an optional vaccine (Shay et al., 2016).  A lack of provider 
recommendation greatly decreases the chance that parents are going to accept HPV vaccine 
(Aragones et al., 2016; Gerend et al., 2016; Shay et al., 2016).  HPV vaccine is recommended at 
age 11-12, Tdap and a meningococcal vaccine are also recommended at this time; the 
presumptive style of vaccine discussion for Tdap and meningococcal vaccine creates a much 
greater acceptance rate (Shay et al., 2016).  Some providers discuss HPV vaccine with parents 
but use passive and weak language; common weak recommendations include: (a) emphasizing 
that is parental choice whether or not their child receives HPV vaccine, (b) advising parents that 
HPV vaccine is not a school requirement, and (c) explaining that vaccinating today is not 
necessary (Shay et al., 2016).  Gerend et al. (2016) found many participants received no 
recommendation from their provider for HPV vaccine during their visits.   
 Insufficient knowledge about HPV and HPV vaccine.  Another barrier to not receiving 
HPV vaccine is lack of knowledge.  The populations studied varied from no knowledge about 
HPV and HPV vaccine to limited knowledge, which made the decision makers hesitant to 
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receive HPV vaccine (Aragones et al., 2016; Dayal et al., 2016; Sanderson et al., 2017; Wilson et 
al., 2016).  Study participants were unsure of the vaccine efficacy (Dayal et al., 2016), what the 
vaccine was protecting against (Aragones et al., 2016; Wilson et al., 2016), and consequences of 
contracting HPV (Aragones et al., 2016; Wilson et al., 2016).  When providers are not providing 
knowledge about HPV and sequalae, the first step toward primary prevention is lost.  Most of the 
decision makers stated that if a provider had offered as much information about HPV and the 
vaccine as the focus group provided, HPV vaccine would have been accepted at their visit 
(Aragones et al., 2016; Wilson et al., 2016). 
 Sexual activity.  Another main concern about initiation of HPV vaccine involved sexual 
activity.  Some parents believed that their child did not need to receive the vaccine because their 
child was not sexually active (Sanderson et al., 2017).  Other parents feared that giving them the 
vaccine would cause an earlier sexual debut or make the child feel safe to engage in riskier 
sexual behaviors (Wilson et al., 2016).   
Factors that Increase HPV Vaccine Uptake 
 The three main factors that increase HPV vaccine uptake are: (a) discussing HPV and 
HPV vaccine; (b) parental awareness and acceptance; and (c) provider recommendation 
(Argones et al, 2016; Dayal et al., 2016; Gerend et al., 2016, Sanderson et al., 2017, Shay et al., 
2016; Wilson et al., 2013).  The strongest predictor of HPV vaccine uptake is provider 
recommendation (Dayal et al., 2016; Gerend et al., 2016, Sanderson et al., 2017, Shay et al., 
2016; Wilson et al., 2013).   
 Discussing HPV and HPV vaccine.  To increase parental consent of HPV vaccine for 
their child, the parent must be knowledgeable about HPV and what HPV vaccine protects against 
(Aragones et al., 2016; Dayal et al., 2016; Shay et al., 2016; Wilson et al., 2016).  When parents 
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learned that HPV is associated with cancers, they stated that they were going to get eligible 
children vaccinated as soon as possible (Aragones et al., 2016; Wilson et al., 2016).  Many 
parents have limited knowledge about HPV and when HPV vaccine is appropriate, thus it is the 
provider’s role to present parents with this information and answer questions so they can make 
an informed decision (Aragones et al., 2016; Wilson et al., 2016).  
 Parental acceptance.  Initiation of HPV vaccine is recommended at age 11-12 (AAP, 
2017; CDC, 2016).  At this age, the parents must consent to vaccines; therefore, parental 
acceptance is important.  Aragones et al. (2016) and Dayal et al. (2016) both discussed how 
empowering the parents will increase acceptance of HPV vaccine leading to initiation of the 
HPV vaccination. 
 Provider recommendation.  Provider recommendation has the most significant 
influence on HPV vaccine uptake (Dayal et al., 2016; Gerend et al., 2016, Sanderson et al., 2017, 
Shay et al., 2016; Wilson et al., 2013).  Patients and parents have built a relationship with their 
providers and that bond creates trust (Aragones et al., 2016).  Families that received a provider 
recommendation were four times more likely to receive the HPV vaccine at that visit (Sanderson 
et al., 2017).  A strong provider recommendation will increase the acceptance of HPV vaccine.  
A strong provider recommendation of HPV vaccine includes explaining why it is the optimal 
time to vaccinate, providing rationale why HPV vaccination is important, and presumptive 
presentation of HPV vaccine (Shay et al., 2016).   
Previous Interventions to Promote HPV Vaccine 
 Sanderson et al. (2017) designed an intervention using four clinics that provided 
healthcare for the underserved in Tennessee; two clinics continued with usual care and two 
clinics received provider/staff training sessions and provisions of patient education materials.  
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The focus of the intervention was on patient education materials, provider and staff training, and 
intervention protocol.  The patient education material group had one team create educational 
videos with four three- to five-minute versions of age specific videos (Sanderson et al., 2017).  
The provider and staff training was taught by a lead investigator who delivered a one-hour 
training session to the pediatric providers, nurses, and medical assistants; the training session that 
covered factual information on HPV associated cancers, HPV vaccination guidelines, and how to 
follow the intervention protocols (Sanderson et al., 2017).   The intervention protocol starts with 
the nurse/medical assistant giving the family the informational flyer and having them fill out the 
questionnaire listed at the top.  Based on the answers, the appropriate version of the video is 
played for them while waiting for the provider.  The provider, during the visit, is to answer any 
questions the family may have and provide a strong recommendation for getting HPV vaccine 
(Sanderson et al., 2017).  After twelve months of intervention, the intervention site had a higher 
vaccination rate at 45.4% versus the usual care site with a 32.9% vaccination rate (Sanderson et 
al., 2017).    
 Brewer et al. (2017) conducted a parallel group randomized clinical trial with thirty 
pediatric and family medicine clinics in North Carolina; the clinics were randomized to receive 
no training, announcement training, or conversational training.  The no training group was the 
control group, the announcement group used brief statements that assume parents are ready to 
vaccinate, and the conversation group engaged parents in conversation and open-ended 
discussion (Brewer et al., 2017).  After six months, HPV vaccination coverage was larger for 
patients in clinics that received announcement training compared to the control clinic; and clinics 
that received conversation training did not differ from the control clinics (Brewer et al., 2017).   
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 Cassidy, Braxter, Charron-Prochownick, and Schienk (2014) conducted a quality 
improvement initiative to increase HPV vaccine rates in a small pediatric practice.  Their 
intervention included an education brochure for the families that included frequently asked 
questions and culturally sensitive pictures of mothers and grandmothers of varied races with their 
daughters, a script for providers to follow when discussing HPV vaccine with families, and 
training for staff that included general information about HPV and HPV vaccine, as well as the 
protocol for the use of the brochure and script (Cassidy et al., 2014).  At the end of the thirteen-
month prospective review the HPV vaccine rates were compared between the groups; the 
intervention group had a 75% uptake rate while the control group had a rate of 24.1%, indicating 
a significantly greater rate of HPV vaccine acceptance in the intervention group (Cassidy et al., 
2014).   
Limitations of Previous Studies 
 A common limitation of the previous studies on HPV vaccine uptake was small sample 
size and limited population diversity.  Studies that included limited diversity and sample size 
included one that conducted a focus group with only ethnically diverse black women (Wilson et 
al., 2013) and one that only studied female uptake of HPV vaccine (Dayal et al., 2016).  The 
influence of only studying one gender may be because of biased parental views on increased 
importance of vaccinating daughters over sons. Cassidy et al. (2014) and Dayal et al. (2016) 
focused their demographics to only the female population.  Many parents that know about HPV 
and HPV vaccine associate the HPV vaccine to preventing cervical cancer and do not understand 
the need to vaccinate their sons (Dayal et al., 2016).  Argones et al. (2016) was also limited in 
diversity; their study only focused on Latino immigrant parents.  Another limitation of the 
Argones et al. (2016) study was the use of parental report on their child’s HPV vaccine status.  
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To reduce recall bias, this author obtained HPV vaccine status through the patients’ electronic 
health record.  Lastly, Sanderson et al. (2017) found that their limitations were non-random 
assignment and limited diversity in patient population.  Matching patients or randomized control 
trials would allow the results to be more reliable and generalizable.   
Conclusions From Literature Review 
 The literature reviewed allowed this author to determine factors that increased and 
decreased the acceptance of HPV vaccine, that a provider recommendation was the strongest 
indicator for HPV vaccine acceptance, and successful strategies from previous studies on 
increasing HPV vaccine compliance.  Using this information, this author created a quality 
improvement plan combining successful strategies and indicators, while avoiding factors that 
decrease HPV vaccine compliance.  Pitfalls of previous studies included small sample size, 
limited diversity, and non-randomized control trials.  While some of these were unavoidable this 
author included both genders and attempted to match control and intervention population 
demographics. 
Purpose and Research Question 
  The purpose of this doctor of nursing practice (DNP) project is to determine if a provider 
recommendation increased HPV vaccine uptake.  Primary prevention is the key to decreasing the 
spread of HPV (Scott & Batty, 2016).  HPV has high lifetime incidence probability and HPV 
vaccine is safe and effective (Dayal et al., 2016; Rahman et al., 2015).  Barriers to HPV vaccine 
acceptance include lack of awareness of vaccine benefits, perceived harm from the vaccine, and 
concerns of increased sexual activity or debut of sexual activity (Dayal et al., 2016; Sanderson et 
al., 2017; Wilson, Brown, Booth, & Harris, 2013).  Factors that increase vaccine acceptance 
include discussion of HPV and HPV vaccine, increasing knowledge of the disease and sequelae, 
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benefits of HPV vaccine, effectiveness of HPV vaccine, and a provider recommendation (Dayal 
et al., 2016; Gerends et al., 2016; Sanderson et al., 2017; Wilson et al., 2013).  Using knowledge 
gained from the literature review, this quality improvement project will focus on the question: 
“In pediatric patients, does a provider recommendation, compared to HPV vaccine as an optional 
vaccine, increase vaccine uptake?” 
Setting 
The setting for this DNP project was a private pediatric practice in Prairie Village, KS.  
There are three partners at this practice, two are medical doctors and one is a doctor of 
osteopathic medicine.  Additionally, there are five nurse practitioners, two with a focus in 
pediatrics and three who are family nurse practitioners.  This practice offers care to patients from 
birth through college.  The demographic of the patients are primarily Caucasian and privately 
insured.  This practice does not accept Medicaid; therefore, the remaining patients are self-pay.  
This practice collaborates with Children’s Mercy Hospital, which allows providers to easily 
access their patient notes from a Children’s Mercy Hospital electronic system.  Children’s Mercy 
Hospital has requirements for collaboration and one of the requirements mandated to this 
practice was increasing HPV vaccine compliance rates.  Routine practice at this practice site 
prior to intervention was to start the discussion of HPV vaccine at the patient’s 11-year well 
child visit.  Providers discussed with parents that recommended vaccines at the visit are Tdap, 
meningococcal, and HPV vaccine; school requires Tdap and meningococcal vaccines, while 
HPV vaccine is an optional vaccine and not required by schools.   
 
 
 
13 
 
Methods 
Theoretical Framework 
 The model that guided this project is the Model for Improvement. The Model for 
Improvement has two parts: three fundamental questions and the Plan-Do-Study-Act (PDSA) 
cycle (see Figure 1) (Institute for Healthcare Improvement [IHI], 2017).  The three questions are: 
(a) what are we trying to accomplish? (setting aims); (b) how will we know that a change is an 
improvement? (establishing measures); and (c) what change can we make that will result in 
improvement? (selecting changes).  The next step is to proceed to the PDSA cycle to test the 
change in the work setting this cycle allows for action-oriented learning (IHI, 2017).   
Figure 1: Plan Do Study Act 
 
Figure 1: This cycle allows a change to be tested and improved before it is initated on a large 
scale.  Adapted from Barbe et al. (2018). 
 
Author’s Assumptions 
 This author’s assumptions, based on information obtained from the literature review, 
were that parents are not well-informed about HPV and HPV vaccine.  Many parents have 
expressed that they did not know about HPV, the consequences of HPV infection, and that there 
is a vaccine available to prevent cancers and warts.  When participants were presented with the 
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knowledge and were provided reassurance that HPV vaccine is not harmful, most parents were 
interested in vaccinating their children and disseminating the importance of HPV vaccine with 
friends and family members.  Studies have shown that with increased knowledge about HPV and 
HPV vaccine and announcing the need to vaccinate, parents will have an increased rate of 
acceptance.  Combining strategies of previous studies, this author assumed that increasing 
parental awareness about HPV and HPV vaccine, co-administration with Tdap and 
meningococcal vaccine, provider reassurance, and provider recommendation would increase 
parental acceptance of HPV vaccine for their child.   
Project Design and Rationale 
 The aim of this project was to increase the proportion of parents that consented to HPV 
vaccine at the visit. To evaluate the effectiveness of the intervention, data collection, analysis, 
and evaluation was conducted one month after intervention initiation to determine if there was at 
least a 10% increase in HPV vaccine acceptance; if a 10% increase did not occur additional an 
additional intervention will be added.   
Protocol.  All the providers consented to participate in the intervention and attended a 
training session.  The training session discussed HPV infection, HPV vaccine benefits, the 
importance of educating patients and parents on HPV infection and HPV vaccine, presumptive 
presentation of HPV vaccine, and co-administration with Tdap and meningococcal vaccine.  The 
training session instructed providers to recommend the first dose of HPV vaccine at the 11-year 
well child visit in addition to recommending Tdap and Menactra®, the meningococcal vaccine.  
The most effective way to increase vaccine uptake is provider recommendation and this 
presumptive style of recommendation increases the likelihood of acceptance because parents 
must opt out of the vaccine versus opting in (Dayal et al., 2016; Gerend et al., 2016, Sanderson et 
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al., 2017, Shay et al., 2016; Wilson et al., 2013).  The providers were reminded to educate 
parents why the visit was the optimal time for HPV vaccination and education on benefits and 
safety of the vaccine.  Parental awareness and knowledge increases parental acceptance and 
desire to vaccinate their child (Aragones et al., 2016; Dayal et al., 2016; Shay et al., 2016; 
Wilson et al., 2016).  The providers were instructed to educate parents that declined Gardasil 9® 
that it only requires a two-dose series versus a three-dose series if the vaccine is initiated before 
age 15 (Merck, 2017).  There was also a practice change for patients receiving a well child exam 
other than the 11-year check that had not initiated or completed the HPV series.  The provider 
will remind patient and parent that they are due for an HPV vaccine and recommend 
administration at the visit.  See Figure 2 for a step-wise algorithm for HPV discussion and 
education initiated by the pediatric provider. 
Project Sample and Selection Process 
 The participants for the study were any pediatric patient, aged 11 or 12 years, receiving a 
well exam that had not completed their HPV vaccine series. Patients under 11 years were 
excluded based on AAP (2017) and CDC (2016) recommendations to begin HPV vaccine series 
at 11 to 12 years.  The electronic health record was used to determine if HPV vaccine was 
ordered and given at the visit. 
Data Collection  
 The DNP student conducted a retrospective chart review to collect data using the 
electronic health record system.  This system determined how many patients in the sample 
population received or declined HPV vaccine in the two months prior to intervention.  
Demographic information was also collected to include, age, race, and gender (see Appendix B 
for data collection form).  Finally, visit provider was determined and recorded.  The same data 
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was collected at the one- and two-month mark after initiating the intervention to determine the 
HPV compliance rates.     
Figure 2: Practice Change Algorithm 
 
Figure 2: This algorithm provides a stepwise approach on how to discuss HPV vaccine with 
patients and parents. 
Results 
 A total of 262 adolescents were analyzed after excluding patient visits for individuals that 
had completed their HPV vaccine series.  HPV vaccine acceptance rates increased from 41.25% 
pre-intervention to 47.8% post-intervention.   After the one-month mark there was not a 10% 
increase in HPV vaccine acceptance rate, therefore an additional intervention was added.  Based 
Is patient 11 years old?
Yes
Recommend Tdap, 
meningococcal, and HPV 
vaccines
Did parents accept HPV 
vaccine?
Yes No
Educate parents about the 
benefits of HPV vaccine and 
that Gardasil 9® only 
requires 2-does when initated 
prior to age 15
No
Has patient completed HPV 
vacine series?
Yes No
Recommend HPV vaccine
Did parents accept HPV 
vaccine?
Yes No
Provide education of the 
benefits of HPV vaccine and 
why it should be initated
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on the literature review, the DNP student decided to increase parental awareness using a bulletin 
board that provided facts about HPV infection and HPV vaccine (see Figure 3).   
Figure 3: Bulletin Board of HPV and HPV Vaccine Facts 
 
Figure 3: This bulletin board was added to all seventeen exam rooms to increase parental 
knowledge and awareness about HPV and HPV vaccine.  Parents could read information at their 
own pace 
 
The use of a bulletin board increased HPV vaccine acceptance rate from 43.88% after the first 
month of intervention, to 60.47% two months post intervention (see Figure 4).  
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Figure 4: HPV Vaccine Acceptance Percentages 
 
Figure 4: Line graph depicting HPV vaccine acceptance percentages.  April and May were pre-
intervention, August was post-intervention with provider recommendation only, and September 
was post-intervention with provider recommendation and bulletin board placement. 
 
There were not clinically significant differences in acceptance rates when comparing age, 
gender, or race/ethnicity (see Table 1).   
Table 1 
Adolescent Characteristics as a Percentage that Received or Did Not Receive HPV Vaccine 
 
 Received HPV Vaccine Did Not Receive HPV Vaccine 
Characteristics Pre-intervention Post-intervention Pre-intervention Post-intervention 
Age     
  11 years 48.48 49.43 51.06 44.21 
  12 years 51.52 50.57 48.94 55.79 
Gender     
  Male 57.58 56.32 65.96 56.84 
  Female 42.42 43.68 34.04 42.16 
Race     
  White 84.85 87.36 85.11 86.32 
  Black 12.12 11.49 10.64 6.32 
  Asian 0 1.15 4.26 2.11 
  Other 3.03 0 0 5.26 
Note. Numbers reported are percentages of the total for those that received HPV vaccine and 
those that did not receive vaccine. 
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However, there was quite a bit of variability of acceptance rates with each provider (see Table 2).  
This variability could be due to a variety of reasons including provider remembering to 
recommend HPV vaccine, parental acceptance of knowledge provided at the visit, parental 
thoughts about adolescent’s possibility of being or becoming sexually active and/or potential to 
contract HPV, and parental views on vaccines. 
Table 2 
Provider Pre- versus Post-Intervention Percentages of Adolescents that Received or Did Not 
Receive HPV Vaccine 
 
 Received HPV Vaccine Did Not Receive HPV Vaccine 
Provider Pre-intervention Post-intervention Pre-intervention Post-intervention 
  1 23.53 56.76 76.47 43.24 
  2 50 50 50 50 
  3 41.67 35 58.33 65 
  4 0 41.18 100 58.82 
  5 0 66.67 0 33.33 
  6 33.33 38.46 66.67 61.54 
  7 100 64.71 0 35.29 
  8 50 25 50 75 
Note. Numbers reported are percentages of the total for those that received HPV vaccine and 
those that did not receive vaccine. 
 
Discussion 
 Previous studies determined provider recommendation to be the most effective method to 
increase HPV vaccine update.  Other methods included parental awareness and acceptance.  This 
study found that provider recommendation alone did not increase HPV vaccine uptake.  The 
addition of a bulletin board to increase parental awareness about HPV infection and HPV 
vaccine did create clinically significant increase in HPV vaccine acceptance.   
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Limitations 
 This study did not have much racial/ethnic diversity, creating a limitation in 
generalizability for other populations.  This practice also tends to care for patients of a higher 
socioeconomic status because they only accept private insurance and do not accept Medicaid.   
Implications for Practice 
 The use of provider recommendation and parental awareness could be used in other 
clinics to increase HPV vaccine uptake.  This strategy should be used with different populations 
to determine the generalizability of this study.  The implementation could also be used for a 
longer duration and target when adolescents are most likely to come in for exams.  This study 
noted an increase of well visits over the summer when adolescents are not in school and need 
well checks to be able to participate in sports the following year. 
Conclusion 
 The quality improvement measure was effective for an affluent, well-educated population 
that was mostly Caucasian, but it still did not raise the uptake rate to meet the acceptance rates of 
Tdap and meningococcal vaccines.  To further increase HPV vaccine acceptance rates future 
studies should be conducted on why parents accept vaccines.   
 This study determined that adding the element of parental awareness increased parental 
acceptance of HPV vaccine.  Future studies could conduct focus groups on how patients and 
parents prefer learning.  During the study period, it was observed that families had to wait in 
exam rooms allowing them time to read the bulletin boards.  This suggests that future studies 
could use this time to educate patients on topics the practice deems necessary.  Could it have 
been possible that the adolescent learned more about HPV infection and HPV vaccine from the 
bulletin board and asked their parent to accept HPV vaccine?  There are many possible reasons 
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that this method was effective, therefore future studies should be conducted at additional 
practices using provider recommendation in addition to bulletin board. 
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Appendix A 
Memoranda of Agreement 
Village Pediatrics L.L.C., agrees to allow Mei Suen, RN, BSN to conduct a Quality 
Improvement project at this location.  This organization understand the Quality Improvement 
project is implementing a provider recommendation to attempt to increase human papillomavirus 
(HPV) vaccine compliance.  Mei Suen will be allowed to access the electronic health system to 
obtain vaccine acceptance vs declination rates and patient demographic information.   
This intervention will span over approximately three months and require a brief provider 
education session.  Patient contact will only be with the provider and not the researcher, 
therefore not requiring a consent form from the patients.   
Comparisons will be made using retrospective analysis of vaccine compliance prior to 
initiation of the intervention, and then again two months after the start of the intervention.  
Results will be provided to the facility. 
 
 
 
Jill Nakayama, RN, BSN 
Nurse Manager 
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Appendix B 
Data Collection Form 
Provider Name  
Age  
Race White       Black       Other (specify): 
Gender Male                       Female                 Transgender 
Accepted HPV vaccine?          Yes                                           No 
 
Provider Name  
Age  
Race White       Black       Other (specify): 
Gender Male                       Female                 Transgender 
Accepted HPV vaccine?          Yes                                           No 
 
Provider Name  
Age  
Race White       Black       Other (specify): 
Gender Male                       Female                 Transgender 
Accepted HPV vaccine?          Yes                                           No 
 
 
